Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots
Diagnostic Test: PET/MRI
Other: Blood and urine sampling
Procedure: laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection

First Posted Date: 2019-11-19

Last Posted Date: 2025-02-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04167969

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2

Recruiting

Conditions: Rectal Adenocarcinoma
Clinical Stage: Stage II (T3-4, N-)
Stage III (Any T, N+)
Solid Tumor
Solid Tumor, Adult

Interventions: Drug: TSR-042 or Dostarlimab
Drug: capecitabine or 5-FU
Radiation: Intensity Modulated Radiation Therapy (IMRT)

First Posted Date: 2019-11-18

Last Posted Date: 2025-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT04165772

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge, New Jersey, United States
🇺🇸
New York Cancer and Blood Specialists, Babylon, New York, United States
🇺🇸
Hartford Healthcare (Data Collection), Hartford, Connecticut, United States

and more 8 locations

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Phase 1

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Atezolizumab
Biological: RO7198457
Drug: mFOLFIRINOX

First Posted Date: 2019-11-13

Last Posted Date: 2025-01-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT04161755

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 4 locations

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Phase 1

Active, not recruiting

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Nivolumab
Drug: Pemetrexed
Drug: Cisplatin or Carboplatin

First Posted Date: 2019-11-13

Last Posted Date: 2024-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT04162015

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Completed

Conditions: Esophagogastric Cancer
Esophageal Cancer
Gastric Adenocarcinoma
Esophagus Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Squamous Cell Carcinoma

Interventions: Drug: IV 18F-BMS-986229
Drug: 18F-BMS-986229 Injection
Diagnostic Test: PET/CT Scan

First Posted Date: 2019-11-13

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04161781

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Phase 2

Active, not recruiting

Conditions: B Cell ALL
B-Cell Lymphoma
B-cell Non Hodgkin Lymphoma

Interventions: Drug: Anakinra

First Posted Date: 2019-11-01

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 62

Registration Number: NCT04148430

Locations: 🇺🇸
Hackensack Meridian Health (Data collection only), Hackensack, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

Phase 2

Recruiting

Conditions: Liver Metastases

Interventions: Diagnostic Test: [18-F]- FDG - PET
Procedure: Tumor ablation (TA)
Diagnostic Test: PET/CT Scan

First Posted Date: 2019-10-29

Last Posted Date: 2025-03-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT04143516

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Pancreatic Cancer
Pancreatic Neoplasms
Pancreatic Adenocarcinoma
Pancreatic Cancer

Interventions: Drug: anti-EGFR-bispecific antibody armed activated T-cells

First Posted Date: 2019-10-24

Last Posted Date: 2025-05-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT04137536

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Virginia (Specimen Analysis), Charlottesville, Virginia, United States

Supportive Care Delivered by Telemedicine to Cancer Patients at Home

Not Applicable

Active, not recruiting

Conditions: Supportive Care
Cancer

Interventions: Other: In-person in clinic follow-up visit
Other: Telemedicine follow-up visit

First Posted Date: 2019-10-23

Last Posted Date: 2024-11-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT04136340

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Phase 2

Active, not recruiting

Conditions: Endometrial Carcinosarcoma
Endometrial Adenocarcinoma

Interventions: Drug: Nivolumab
Drug: BMS- 986205

First Posted Date: 2019-09-27

Last Posted Date: 2025-05-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT04106414

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy